Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
| Title | Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC |
|---|---|
| Description | The study will submit its CSR data to Health authority of different countries. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA012345 |
| Release Date | 2022-12-31 |
| Submitter | Changli Wang (wangchangli309@163.com) |
| Organization | Tianjin Cancer Hospital |
| Submission Date | 2022-10-08 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002023-03 | CA209-816 biomaker data | 2 | Biomarker Data | 918.6 KB | rar | 0 | Controlled |